Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Novavax Inc NVAX

Healthcare Biotechnology
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID... see more

Recent & Breaking News (NDAQ:NVAX)

Wall Street Fundamentals Releases New In-Depth Stock Reports on ARRY, GNVC, IDIX and NVAX

Accesswire September 16, 2013

Novavax Highlights Positive Results From Partner's Clinical Trial of Vaccine Using Matrix-M(TM)

Globe Newswire September 13, 2013

Genocea Reports Positive Initial Phase 1/2a Results for GEN-003, its Pioneering Therapeutic Vaccine Candidate for the Treatment of Herpes Simplex Virus-2 (HSV-2), at ICAAC 2013

PR Newswire September 12, 2013

ICAAC Presentations Highlight Potential Protective Effects of Novavax' RSV Vaccine Candidate

Globe Newswire September 11, 2013

Novavax to Present at the 2013 Stifel Nicolaus Healthcare Conference

Globe Newswire September 5, 2013

Novavax to Present RSV Vaccine Clinical and Preclinical Results at ICAAC

Globe Newswire September 3, 2013

Genocea Biosciences Selected To Present Late-Breaking Oral Presentation At ICAAC 2013

PR Newswire August 28, 2013

TSLA, GMCR, NVAX and SLM added to NASDAQ Active Stock Watch List at EPR

Accesswire August 20, 2013

Novavax Reports Second-Quarter 2013 Financial Results

Globe Newswire August 8, 2013

Novavax to Report Second Quarter 2013 Financial Results on August 8, 2013

Globe Newswire August 1, 2013

Five Star Equities Issues New Research Reports on CHTP, ELN, ISIL and NVAX

Accesswire July 30, 2013

Novavax Publishes Positive Preclinical Efficacy Data Against Influenza A(H7N9)

Globe Newswire July 29, 2013

Wall Street Fundamentals Releases New In-Depth Stock Reports on CYTK, DNDN, IMGN and NVAX

Accesswire July 17, 2013

GenScript's Rush Gene Services Help Novavax Expedite 28-day Development of H7N9 Vaccine

PR Newswire July 8, 2013

GenScript's Rush Gene Services Help Novavax Expedite 28-day Development of H7N9 Vaccine

PR Newswire July 8, 2013

GenScript's Rush Gene Services Help Novavax Expedite 28-day Development of H7N9 Vaccine

Canada NewsWire July 8, 2013

Novavax Initiates First Phase 1 Clinical Trial of Its A(H7N9) Influenza Vaccine Candidate

Globe Newswire July 8, 2013

Wall Street Fundamentals Releases New In-Depth Stock Reports on EXEL, NVAX, SQNM and VVUS

Accesswire July 2, 2013

Novavax Announces Positive Top-Line Results From Phase 1 Clinical Trial of RSV Vaccine Candidate in Elderly

Globe Newswire July 2, 2013

Pre-Market Review: MannKind, Ariad Pharma, Galena Biopharma, and Novavax

PR Newswire June 28, 2013